Temsirolimus improves cytotoxic efficacy of cisplatin and gemcitabine against urinary bladder cancer cell lines

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 1, 2014, Pages 41.e11-41.e22

  Pinto Leite, Rosário ^a   Arantes Rodrigues, Regina ^b   Ferreira, Rita ^c   Palmeira, Carlos ^d,e   Colaço, Aura ^b   Moreira da Silva, Vítor ^d   Oliveira, Paula ^f   Lara Santos, Lúcio ^d,e  

^a Hospital Center of Tras os Montes and Alto Douro   (Portugal)

^b UNIVERSITY OF TRÁS OS MONTES AND ALTO DOURO   (Portugal)

^c UNIVERSITY OF AVEIRO   (Portugal)

^d PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^e UNIVERSIDADE FERNANDO PESSOA   (Portugal)

^f UNIVERSITY OF PORTO   (Portugal)

Author keywords

Bladder cancer cell lines; Cisplatin; Combination chemotherapy; Gemcitabine; Temsirolimus

Indexed keywords

CISPLATIN; GEMCITABINE; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; TEMSIROLIMUS;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; BLADDER CANCER; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE G0 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PRIORITY JOURNAL;

BLADDER CANCER CELL LINES; CISPLATIN; COMBINATION CHEMOTHERAPY; GEMCITABINE; TEMSIROLIMUS;

ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOPHAGY; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HUMANS; IMMUNOBLOTTING; MICROSCOPY, FLUORESCENCE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIROLIMUS; TOR SERINE-THREONINE KINASES; URINARY BLADDER NEOPLASMS;

EID: 84890786642     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2013.04.012     Document Type: Article

References (55)

1. Boni J.P., Hug B., Leister C., Sonnichsen D. Intravenous temsirolimus in cancer patients: clinical pharmacology and dosing considerations. Semin Oncol 2009, 3:S18-S25.
2. Bukowski R.M. Temsirolimus: a safety and efficacy review. Expert Opin Drug Saf 2012, 11:861-879.
3. Wacheck V. mTOR pathway inhibitors in cancer therapy: moving past rapamycin. Pharmacogenomics 2010, 11:1189-1191.
4. Carew J.S., Kelly K.R., Nawrocki S.T. Mechanisms of mTOR inhibitor resistance in cancer therapy. Target Oncol 2011, 6:17-27.
5. O'Reilly T., McSheehy P.M., Wartmann M., Lassota P., Brandt R., Lane H.A. Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo. Anticancer Drugs 2011, 22:58-78.
6. Pópulo H., Lopes J.M., Soares P. The mTOR signalling pathway in human cancer. Int J Mol Sci 2012, 13(2):1886-1918.
7. Baxi S.M., Walls M., Cheng H., Yin M.J. Targeting the mTOR pathway in tumor malignancy. Curr Cancer Drug Targets 2013, [Epub ahead of print].
8. Sun Y., Rha S., Lee S.H., Guo J., Ueda T., Qin S., et al. Phase II study of the safety and efficacy of Temsirolimus in East Asian patients with advanced renal cell carcinoma. Jpn J Clin Oncol 2012, 42:836-844.
9. Fleming G.F., Ma C.X., Huo D., Sattar H., Tretiakova M., Lin L., et al. Phase II trial of temsirolimus in patients with metastatic breast cancer. Breast Cancer Res Treat 2012, 136(2):355-363.
10. Geoerger B., Kieran M.W., Grupp S., Perek D., Clancy J., Krygowski M., et al. Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma. Eur J Cancer 2012, 48:253-262.
11. Oza A., Elit L., Tsao M.S., Kamel-Reid S., Biagi J., Provencher D.M., et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol 2011, 29:3278-3285.
12. Ansell S.M., Tang H., Kurtin P.J., Koenig P.A., Inwards D.J., Shah K., et al. Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a Phase 2 study. Lancet Oncol 2011, 12:361-368.
13. Shor B., Zhang W.G., Toral-Barza L., Lucas J., Abraham R.T., Gibbons J.J., et al. A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis. Cancer Res 2008, 68:2934-2943.
14. Pal S., Figlin R.A. Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma. Target Oncol 2011, 6:5-16.
15. Ito D., Fujimoto K., Mori T., Kami K., Koizumi M., Toyoda E., et al. In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer. Int J Cancer 2006, 118:2337-2343.
16. Wolff A., Lazar A.A., Bondarenko I., Garin A.M., Brincat S., Chow L., et al. Randomized Phase III placebo-controlled trial of Letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol 2013, 31(2):195-202.
17. Gerullis H., Ecke T.H., Janusch B., Arndt C., Heidari M., Oniani J., et al. Long-term response in advanced bladder cancer involving the use of temsirolimus and vinflunine after platin resistance. Anticancer Drugs 2011, 22:940-943.
18. Pinto-Leite R., Botelho P., Ribeiro E., Oliveira P.A., Santos L. Effect of sirolimus on urinary bladder cancer T24 cell line. J Exp Clin Cancer Res 2009, 28:3.
19. Fechner G., Classen K., Schmidt D., Hauser S., Müller S.C. Rapamycin inhibits in vitro growth and release of angiogenetic factors in human bladder cancer. Urology 2009, 73(3):665-668.
20. Makhlin I., Zhang J., Long C.J., Devarajan K., Zhou Y., Klein-Szanto A.J., et al. The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers. BJU Int 2011, 108:E84. E90.
21. Chiong E., Lee I.L., Dadbin A., Sabichi A.L., Harris L., Urbauer D., et al. Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells. Clin Cancer Res 2011, 17:2863-2873.
22. Mansure J.J., Nassim R., Chevalier S., Rocha J., Scarlata E., Kassouf W. Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer. Cancer Biol Ther 2009, 8:2339-2347.
23. Makhov P.B., Golovine K., Kutikov A., Teper E., Canter D.J., Simhan J., et al. Modulation of Akt/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells. Mol Cancer Ther 2012, 11:1510-1517.
24. Martin B., Edeline J., Patard J.J., Oger E., Jouan F., Boulanger G., et al. Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines. J Cancer Res Clin Oncol 2012, 138:907-916.
25. Zhang W., Haines B.B., Efferson C., Zhu J., Ware C., Kunii K., et al. Evidence of mTOR activation by an AKT-independent mechanism provides support for the combined treatment of PTEN-deficient prostate tumors with mTOR and AKT inhibitors. Transl Oncol 2012, 5:422-429.
26. Niemann A., Takatsuki A., Elsässer H.P. The lysosomotropic agent monodansylcadaverine also acts as a solvent polarity probe. J Hist Cytochem 2000, 48:251-258.
27. Leers M.P., Kölgen W., Björklund V., Bergman T., Tribbick G., Persson B., et al. Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol 1999, 187:567-572.
28. Vasconcelos-Nóbrega C., Pinto-Leite R., Arantes-Rodrigues R., Ferreira R., Brochado P., Cardoso M.L., et al. In vivo and in vitro effects of RAD001 on bladder cancer. Urol Oncol 2011, 10.1016/j.urolonc.2011.11.002.
29. Pinto-Leite R., Arantes-Rodrigues R., Palmeira C., Gaivão I., Cardoso M.L., Colaço A., et al. Everolimus enhances gemcitabine-induced cytotoxicity in bladder-cancer cell lines. J Toxicol Environ Health 2012, 75:788-799.
30. Pinto-Leite R., Arantes-Rodrigues R., Palmeira C., Colaço B., Lopes C., Colaço A., et al. Everolimus combined with cisplatin has a potential role in treatment of urothelial bladder cancer. Biomed Pharmacother 2012, 67(2):116-121.
31. Bellmunt J., Albiol S., Suárez C., Albanell J. Optimizing therapeutic strategies in advanced bladder cancer: update on chemotherapy and the role of targeted agents. Crit Rev Oncol Hematol 2009, 69(3):211-222.
32. Kim J.J. Recent advances in treatment of advanced urothelial carcinoma. Curr Urol Rep 2012, 13(2):147-152.
33. Platt F., Hurst C.D., Taylor C.F., Gregory W.M., Harnden P., Knowles M.A. Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. Clin Cancer Res 2009, 15:6008-6017.
34. Hansel D.E., Platt E., Orloff M., Harwalker J., Sethu S., Hicks J.L., et al. Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma. Am J Pathol 2010, 176:3062-3072.
35. Menon S., Manning B.D. Common corruption of the mTOR signaling network in human tumors. Oncogene 2008, 27:S43-S51.
36. Rostaing L., Kamar N. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?. J Nephrol 2010, 23:133-142.
37. Yazbeck V., Buglio D., Georgakis G.V., Li Y., Iwado E., Romaguera J.E., et al. Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma. Exp Hematol 2008, 36:443-450.
38. Maira S.M., Stauffer F., Brueggen J., Furet P., Schnell C., Fritsch C., et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008, 7:1851-1863.
39. Schedel F., Pries R., Thode B., Wollmann B., Wulff S., Jocham D., et al. mTOR inhibitors show promising in vitro activity in bladder cancer and head and neck squamous cell carcinoma. Oncol Rep 2011, 25:763-768.
40. Yang S., Xiao X., Meng X., Leslie K.K.A. Mechanism for synergy with combined mTOR and PI3 kinase inhibitors. PLoS One 2011, 6:e26343.
41. Wang X., Hawk N., Yue P., Kauh J., Ramalingam S.S., Fu H., et al. Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy. Cancer Biol Ther 2008, 7:1952-1958.
42. Gibbons J.J., Abraham R.T., Yu K. Mammalian target of rapamycin: discovery of rapamycin reveals a signalling pathway important for normal and cancer cell growth. Semin Oncol 2009, 36:S3-S17.
43. Weekes C.D., Song D., Arcaroli J., Wilson L.A., Rubio-Viqueira B., Cusatis G., et al. Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancer. Neoplasia 2012, 14(8):690-701.
44. Zhang H., Berel D., Wang Y., Li P., Bhowmick N.A., Figlin R.A., et al. A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models. PLoS One 2013, 8(1):e54918.
45. Okui T., Shimo T., Fukazawa T., Hassan N.M., Honami T., Ibaragi S., et al. Novel HSP90 Inhibitor NVP-AUY922 enhances the anti-tumor effect of temsirolimus against oral squamous cell carcinoma. Curr Cancer Drug Targets 2012, [Epub ahead of print].
46. Shi W., Xiao D., Wang L., Dong L.H., Yan Z.X., Shen Z.X., et al. Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy. Cell Death Dis 2012, 3:e275.
47. Kilani R.T., Tamimi Y., Karmali S., Mackey J., Hanel E.G., Wong K.K., et al. Selective cytotoxicity of gemcitabine in bladder cancer cell lines. Anticancer Drugs 2002, 13:557-566.
48. Zoli W., Ricotti L., Tesei A., Ulivi P., Campani G.A., Fabbri F., et al. Schedule-dependent cytotoxic interaction between epidoxorubicin and gemcitabine in human bladder cancer cells in vitro. Clin Cancer Res 2004, 10:1500-1507.
49. Donadelli M., Costanzo C., Beghell S., Scupoli M.T., Dandrea M., Bonora A., et al. Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine. Biochim Biophys Acta 2007, 1773:1095-1106.
50. Garcia J.A., Danielpour D. mTOR inhibition as a therapeutic strategy in the management of urologic malignancies. Mol Cancer Ther 2008, 7:1347-1354.
51. Rexer H. Second line AUO (Working Group Urological Oncology) study AB 35/09 on metastasized urothelial carcinoma. Phase II study with RAD001 in combination with paclitaxel for patients with metastasized urothelial carcinoma of the urinary bladder after failure of platinum-based chemotherapy (CRAD001). Urologe A 2011, 50:1464-1465.
52. Drayton R.M., Catto J.W. Molecular mechanisms of cisplatin resistance in bladder cancer. Exp Rev Anticancer 2012, 12:271-281.
53. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
54. Jeong E.H., Choi H.S., Lee T.G., Kim H.R., Kim C.H. Dual inhibition of PI3K/Akt/mTOR pathway and role of autophagy in non-small cell lung cancer cells. Tuberc Respir Dis 2012, 72:343-351.
55. Chiarini F., Lonetti A., Teti G., Orsini E., Bressanin D., Cappellini A., et al. A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia. Oncotarget 2012, [Epub ahead of print].